“Urticaria Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Urticaria Market.
The Urticaria Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Urticaria Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Urticaria treatment therapies with a considerable amount of success over the years.
-
Urticaria companies working in the treatment market are Allakos, AstraZeneca, Biosana, Celldex Therapeutics, Celltrion, Eli Lilly and Company, Genentech, GI Innovation/Yuhan, Regeneron, GlaxoSmithKline, Taiho Pharma, Glenmark Pharmaceuticals, Gossamer Bio, Kiniksa Pharmaceuticals, Mycenax Biotech, Novartis, Regeneron, Synermore Biologics, UCB Biopharma, United BioPharma, and others, are developing therapies for the Urticaria treatment
-
Emerging Urticaria therapies in the different phases of clinical trials are- Ligelizumab, Remibrutinib (LOU064), Tezepelumab, CDX-0159, GI-301, Dupilumab (DUPIXENT), UB-221, MTPS9579A, Lirentelimab (AK002), TAS5315, rilzabrutinib, GDC-0853, AZD1981, Desloratadine, and others are expected to have a significant impact on the Urticaria market in the coming years.
-
In March 2024, Celltrion has submitted a biologics license application (BLA) to the US Food and Drug Administration (FDA) for CT-P39, a biosimilar candidate to XOLAIR (omalizumab), aimed at treating chronic spontaneous urticaria (CSU). This submission marks a crucial step towards introducing an interchangeable biosimilar for CSU treatment. The BLA is supported by evidence, including data from a global Phase III clinical trial comparing CT-P39 to the reference therapy XOLAIR.
-
In January 2024, Evommune has initiated a Phase I first-in-human clinical trial for EVO756, a new oral treatment for chronic spontaneous urticaria (CSU). This trial aims to evaluate the tolerability, safety, and pharmacokinetics of EVO756 in both healthy adults and adult CSU patients. The randomized, placebo-controlled, double-blind study will examine single and multiple ascending doses (SAD and MAD) in healthy participants, while also including an open-label study for CSU patients.
-
In November 2023, Novartis’ remibrutinib successfully met all primary and secondary endpoints at 12 weeks in the Phase III REMIX-1 and REMIX-2 trials for adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines. Remibrutinib, a selective Bruton’s tyrosine kinase (BTK) inhibitor, works by inhibiting histamine release through the BTK pathway. This histamine release is responsible for CSU symptoms such as itching, hives, and swelling.
Urticaria Overview
Urticaria, commonly known as hives, is a skin condition characterized by the sudden appearance of red, itchy welts or wheals on the skin. These welts can vary in size and shape, often merging together to form larger areas of raised skin. Urticaria can be acute, lasting less than six weeks, or chronic, persisting for more than six weeks.
Get a Free Sample PDF Report to know more about Urticaria Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/urticaria-pipeline-insight
Emerging Urticaria Drugs Under Different Phases of Clinical Development Include:
-
Ligelizumab: Novartis
-
Remibrutinib (LOU064): Novartis
-
Tezepelumab: Amgen
-
CDX-0159: Celldex Therapeutics
-
GI-301: GI Innovation
-
Dupilumab (DUPIXENT): Sanofi/ Regeneron
-
UB-221: United BioPharma
-
MTPS9579A: Genentech
-
Lirentelimab (AK002): Allakos Inc.
-
TAS5315: Taiho Pharma
-
rilzabrutinib: Sanofi
-
GDC-0853: Genentech, Inc.
-
AZD1981: AstraZeneca
-
Desloratadine: Organon and Co
Urticaria Route of Administration
Urticaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Parenteral
-
Intravenous
-
Subcutaneous
-
Topical
Urticaria Molecule Type
Urticaria Products have been categorized under various Molecule types, such as
-
Recombinant fusion proteins
-
Small molecule
-
Monoclonal antibody
-
Peptide
-
Polymer
-
Gene therapy
Urticaria Pipeline Therapeutics Assessment
-
Urticaria Assessment by Product Type
-
Urticaria By Stage and Product Type
-
Urticaria Assessment by Route of Administration
-
Urticaria By Stage and Route of Administration
-
Urticaria Assessment by Molecule Type
-
Urticaria by Stage and Molecule Type
DelveInsight’s Urticaria Report covers around 25+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Urticaria product details are provided in the report. Download the Urticaria pipeline report to learn more about the emerging Urticaria therapies
Some of the key companies in the Urticaria Therapeutics Market include:
Key companies developing therapies for Urticaria are – Sanofi, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, Roche, Novartis, GlaxoSmithKline, Allakos, Eli Lilly and Company and others.
Urticaria Pipeline Analysis:
The Urticaria pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Urticaria with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Urticaria Treatment.
-
Urticaria key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Urticaria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Urticaria market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Urticaria drugs and therapies
Urticaria Pipeline Market Drivers
-
Treatment Side Effects with Currently Available Treatment, Economic Burden on Patients, Increase in Research and Development Activities, Increasing Market Size, are some of the important factors that are fueling the Urticaria Market.
Urticaria Pipeline Market Barriers
-
However, Lack of Understanding of Disease Pathology, Approaching Patent Cliff, and other factors are creating obstacles in the Urticaria Market growth.
Scope of Urticaria Pipeline Drug Insight
-
Coverage: Global
-
Key Urticaria Companies: Allakos, AstraZeneca, Biosana, Celldex Therapeutics, Celltrion, Eli Lilly and Company, Genentech, GI Innovation/Yuhan, Regeneron, GlaxoSmithKline, Taiho Pharma, Glenmark Pharmaceuticals, Gossamer Bio, Kiniksa Pharmaceuticals, Mycenax Biotech, Novartis, Regeneron, Synermore Biologics, UCB Biopharma, United BioPharma, and others
-
Key Urticaria Therapies: Ligelizumab, Remibrutinib (LOU064), Tezepelumab, CDX-0159, GI-301, Dupilumab (DUPIXENT), UB-221, MTPS9579A, Lirentelimab (AK002), TAS5315, rilzabrutinib, GDC-0853, AZD1981, Desloratadine, and others
-
Urticaria Therapeutic Assessment: Urticaria current marketed and Urticaria emerging therapies
-
Urticaria Market Dynamics: Urticaria market drivers and Urticaria market barriers
Request for Sample PDF Report for Urticaria Pipeline Assessment and clinical trials
Table of Contents
1. Urticaria Report Introduction
2. Urticaria Executive Summary
3. Urticaria Overview
4. Urticaria- Analytical Perspective In-depth Commercial Assessment
5. Urticaria Pipeline Therapeutics
6. Urticaria Late Stage Products (Phase II/III)
7. Urticaria Mid Stage Products (Phase II)
8. Urticaria Early Stage Products (Phase I)
9. Urticaria Preclinical Stage Products
10. Urticaria Therapeutics Assessment
11. Urticaria Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Urticaria Key Companies
14. Urticaria Key Products
15. Urticaria Unmet Needs
16 . Urticaria Market Drivers and Barriers
17. Urticaria Future Perspectives and Conclusion
18. Urticaria Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Urticaria Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Sanofi, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPhar